A Study of AZD0120 in Autoimmune Diseases
Phase 1
27
about 2.2 years
18–75
8 sites in AZ, CA, IL +5
About this study
Researchers are testing a treatment called AZD0120 for people with autoimmune diseases like idiopathic inflammatory myopathies, rheumatoid arthritis, or systemic sclerosis. The trial will evaluate the safety and tolerability of this treatment in adults.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive AZD0120
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of participants and severity of dose limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs)
Secondary: Cellular Kinetics - AUC, Cellular Kinetics - Cmax, Cellular Kinetics - Tmax, Change from baseline in modified Rodnan Skin Score (mRSS). The mRSS is a measure of skin thickness with a range of 0-51 with higher scores indicating more severe disease., Change from baseline in the Disease Activity Score (DAS) 28-C-reactive protein (CRP). The DAS28-CRP is a measure from 0-10 with higher scores indicating greater disease activity., Change from baseline in the total improvement score (TIS). The TIS ranges from 0-100 with higher scores indicating greater improvement.
Immune